Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great interview with Amber Theoharis about Clickstream. If anyone wants to check it out. Here is the link.
Check interview on RICH TV LIVE with Daniel Bagi.
Great video explaining HPQ Silicon Resources.
Emma Andrews from Bevcanna on RICH TV LIVE.
Check interview of Canadian cbd beverage company Bevcanna.
Esports company EGLX signs LOI with Ubuck from LLT. Check out the video.
Joe Mimran to Join Advisory Committee; Krisztian Toth Appointed to Board of Directors
VANCOUVER, April 9, 2019 /CNW/ - Pivot Pharmaceuticals Inc. (CSE: PVOT / OTCQB: PVOTF / FRA: NPAT) ("Pivot" or the "Company") is pleased to announce that it has signed a Binding Letter of Intent, dated April 8, 2019, with High Park Ventures Inc. ("HPK" or "High Park Ventures"), a private investment company, for a non-brokered private placement of $15 million. The private placement will be of units at a price of $0.25 per unit, with each unit consisting of one common share and one common share purchase warrant ("Warrants") having a term of two years and an exercise price of $0.35. The private placement is expected to close in two tranches, with the first closing of $5 million within two weeks and the second tranche of $10 million closing within four weeks. Upon completion of the non-brokered private placement Pivot will issue 60,000,000 units to HPK. Completion of the private placement is conditional on HPK satisfactorily completing its due diligence investigation and High Park Ventures and Pivot entering into an advisory agreement pursuant to which High Park Ventures will provide Pivot with strategic advice.
?
High Park Ventures is a private investment company with a focus on US investments, whose chairman is renowned entrepreneur Joe Mimran. Upon completion of the closing, Joe Mimran will join Pivot's advisory committee and will provide strategic advice to Pivot. Mr. Mimran is Co-founder and Chairman of Gibraltar and Company, and an internationally recognized brand and retail concept visionary known for brands such as Joe Fresh and Club Monaco. Krisztian Toth, the Chief Executive Officer of High Park Ventures, will join the Board of Pivot on the closing date. The High Park Ventures team previously founded NettaGrowth International Inc. ("NettaGro"), who through Dormul S.A. obtained the first license to produce medical cannabis with THC for commercialization in Uruguay. NettaGro was sold to Khiron Life Sciences Corp. on January 25, 2019.
Pivot's CEO, Dr. Patrick Frankham stated, "We are thrilled to welcome Joe Mimran to Pivot's advisory committee and receive the investment from High Park Ventures. With the investment and support provided by the High Park Ventures Team, we are able to implement and accelerate our initiatives. I would also like to welcome Krisztian Toth to Pivot's Board of Directors. The experience and track record of the High Park Ventures Team will greatly benefit Pivot's management team as we commercialize our industry leading bio-cannabis product line."
Krisztian Toth, CEO of High Park Ventures Inc., "We are excited to work with the Pivot Team and assist them with the development, commercialization and branding of premium quality cannabinoid-based nutraceuticals and pharmaceuticals and leveraging the worldwide rights of their patented drug delivery technologies."
About Pivot Pharmaceuticals Inc.
Pivot Pharmaceuticals Inc. is a science-based consumer packaged goods cannabis company engaged in the development and commercialization of health and wellness products using innovative, patent-protected drug delivery technologies. Upon receipt of a Standard Processor license (pending) from Health Canada, Pivot's premium, bioavailable, stable and effective products will be manufactured at its 50,000-sq. ft. cGMP facility located in Montreal, Quebec. Pivot's wholly-owned U.S. subsidiary, Pivot Naturals, LLC, based in Costa Mesa, California, was granted a Temporary Manufacturing Type N: Infusion License by the California Department of Public Health in November 2018. Pivot's product line includes infused beverages, vegan capsules, dissolvable tablets, topical creams and gels, intimate lubricants, roll-on pain relievers, stick packs, and bulk powder for the edibles market. For more information please visit pivotpharma.com
Cautionary Note Regarding Forward-Looking Statements
Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot Pharmaceuticals Inc., Pivot Green Stream Health Solutions Inc., Pivot Naturals, LLC, or its management or the completion of the private placement, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, such as the failure to close the private placement, meet the conditions imposed by the CSE or other securities regulators, the level of business and consumer spending, the amount of sales of Pivot's products, statements with respect to internal expectations, the competitive environment within the industry, the ability of Pivot to continue to expand its operations, the level of costs incurred in connection with Pivot's expansion efforts, economic conditions in the industry, and the financial strength of Pivot's customers and suppliers. Pivot does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.
Great ceo interview with Russ Mcmeekin from MCLDF. Check it out.
Check out Ceo interview with Russ Mcmeekin from MCLDF.
Ceo interview with Russ Mcmeekin from MCLDF.
Interview with CEO Of MCLD.
Check out the video on MCLDF.
Some good news on green growth brands.
Check out the video
Green Growth Brands might break out. Good news today.
Check out green growth band video. Big news today.
RICH TV LIVE
#1 FREE community for 24/7 Stocks. Join our telegram to be apart of the discussion.
https://t.me/richtvlive
RICH TV LIVE
#1 FREE community for 24/7 Stocks. Join our telegram to be apart of the discussion.
https://t.me/richtvlive
RICH TV LIVE
#1 FREE community for 24/7 Stocks. Join our telegram to be apart of the discussion.
https://t.me/richtvlive
Green Pharma has a chicken farm calling it a hemp farm. Total scam!
These guys are bunch of scammers they have nothing
The only person i blame for losing on a investment is my self because I read and drink the juice by doing my own due diligence
I never pumped I only observed. You must get excited when I talk that's why you see it as promotional. Learn to read and do your due diligence because all these OTC companies are run but guys that's will do what they have to help them selves.
Keep your eye on CXBS it's looking good.
Cmon man you can't compare that to CXBS.
Volume getting stronger and price steadily climbing. Things are looking positive I have to say.
What's your guys thoughts on Cxbs? it's up 21%!
CXBS up 21% looking good!
Cxbs is getting ready to take off. So keep a close and do your own due diligence don't listen to anyone else.
Ogburn seems to be building a real project I had some one go to adelente, Cali. They confirmed the location where OG group is building in Corix building. So looking like real business to me.
I have to agree the chart is looking like it's priming to take off. Good luck to everyone.
Mr Bond what do you suggest we buy?
That is great news. Good to see this company moving in the right direction.
IRVINE, Calif., March 20, 2018 (GLOBE NEWSWIRE) -- Corix Bioscience Inc. (OTCQB: CXBS), an emerging developer of proprietary cannabis and industrial hemp strains earmarked specifically for use in important healthcare applications, today announced that the relocation of OG Group personnel and equipment from Colorado to California is proceeding smoothly.
Corix CEO Michael Ogburn stated, “We are excited that an iconic industry ‘Dream Team’ will be a vital part of Corix Bioscience going forward. I am confident that our joint efforts will result in significant value creation for all of our stakeholders.”
Subject to approval of its standard operating plan by the City of Adelanto, OG Group expects to be functioning near full strength in two to three weeks.
OG Group president Tim Chan said, “In 2018, the California cannabis industry should generate over $7 billion in revenue. Cultivators and distributors know that we have an unparalleled reputation for excellence with respect to the work we do and the results we achieve. We fully expect OG Group will be the leading cannabis extractor in the state this year.”
Anthony Smith, OG Group chief operating officer, commented, “The cannabis industry has not yet seen the unique technology we will utilize at scale in our Adelanto facility. The true extent of what we can do will soon be apparent, and we look forward to a robust demand for our array of value-added services.”
About OG Group
OG Group LLC was recently established by several experienced industry leaders who have revolutionized the cannabis distillery and refinery space. Their background in modern technology and molecular science has allowed them to serially invent ground-breaking products that dominate the market.
One recent innovation that has already generated substantial demand is a service designed to assist cultivators in adapting to the regulation changes in California. To protect consumers, the state has toughened its regulations on residual pesticide levels in cannabis. OG Group has developed a unique molecular procedure that removes the residual pesticides, allowing cultivators’ products to be compliant once again, and also safer for their customers.
Utilizing science and technology, OG Group has become a leading innovator in the cannabis industry, achieving levels of quality that have redefined the standards for cannabis-related products.
About Corix
Corix Bioscience Inc. develops proprietary cannabis and industrial hemp strains using tissue cell cultures to propagate living plants that are free of any pathogen or disease. We grow these plants to maturity and extract the oils, which are the “medicine” part of the plants. We are science-based, knowledge-powered and purpose-driven. Our market focus is on healthcare and we expect to release our initial brand-name products for distribution in the first half of this year.
Our principal executive offices are in Irvine, California. We grow industrial hemp on land we lease near Genoa, Nevada. We also provide industrial hemp and cannabis extraction services in Adelanto, California. Our mission is to create superior-quality products in medical-grade facilities, better for both people and the environment. We invite you to visit us on the Web at www.corixbioscience.com.
Cautionary Note Regarding Forward-Looking Statements
Certain of the statements in this news release that are not statements of historical fact, including, but not limited to, those identified by the use of terms such as "anticipate," "appear," "believe," "could," "estimate," "expect," "hope," "indicate," "intend," "likely," "may," "might," "plan," "potential," "project," "seek," "should," "will," "would," and other variations or negative expressions of these terms, and including statements related to expected market trends and the future business and financial performance of Corix Bioscience Inc., are all "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve a number of risks and uncertainties.
Prospective investors are cautioned not to place undue reliance on any forward-looking statements. Statements made regarding the intent, belief or current expectations of Corix are based on assumptions that Corix management believes are reasonable in light of information available on the date hereof, but they are not guarantees of future performance and are subject to a wide range of known and unknown risks, uncertainties and other factors identified in periodic filings made by Corix with the Securities and Exchange Commission.
Actual future results may differ materially from those indicated by present forward-looking statements. Corix Bioscience Inc. disclaims any obligation to update or revise this news release to reflect any change in the company's expectations or any change in events or circumstances after the date hereof, except as required by law.
Shannon briggs fight should give good advertising for champ Rx and Corix.
This company is getting ready to take off. Some more good news will set it up nicely. George sharp news is getting old. His points are too redundant.